The potential of alkaline phosphatase as a treatment for sepsis-associated acute kidney injury

Nephron - Clinical Practice

Volumn 127, Issue 1-4, 2014, Pages 144-148

  Peters, Esther ^a   Masereeuw, Rosalinde ^a   Pickkers, Peter ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute kidney injury; Adenosine; Alkaline phosphatase; Lipopolysaccharide; Renal inflammation; Sepsis; Systemic inflammation

Indexed keywords

ALKALINE PHOSPHATASE; ENDOTOXIN; ADENOSINE; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE; HYBRID PROTEIN;

ACUTE KIDNEY FAILURE; CELL STRESS; CONFERENCE PAPER; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DEPHOSPHORYLATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; GRAM NEGATIVE BACTERIUM; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SEPSIS; SEPTIC SHOCK; URINARY EXCRETION; ACUTE KIDNEY INJURY; ANIMAL; BOVINE; COMPLICATION; CRITICAL ILLNESS; DEFICIENCY; DRUG EFFECTS; DRUG SCREENING; ENDOTOXEMIA; ENZYMOLOGY; FORECASTING; INTESTINE; METABOLISM; MULTICENTER STUDY (TOPIC); PHYSIOLOGY;

ACUTE KIDNEY INJURY; ADENOSINE; ADENOSINE TRIPHOSPHATE; ALKALINE PHOSPHATASE; ANIMALS; CATTLE; CLINICAL TRIALS, PHASE II AS TOPIC; CRITICAL ILLNESS; DRUG EVALUATION, PRECLINICAL; ENDOTOXEMIA; FORECASTING; HUMANS; INTESTINES; MULTICENTER STUDIES AS TOPIC; RECEPTORS, PURINERGIC P1; RECOMBINANT FUSION PROTEINS; SEPSIS;

EID: 84927704497     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000363256     Document Type: Conference Paper

References (27)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the united states: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
2. Oppert M, Engel C, Brunkhorst FM, Bogatsch H, Reinhart K, Frei U, Eckardt KU, Loeffler M, John S, German Competence Network Sepsis (Sepnet): Acute renal failure in patients with severe sepsis and septic shock-a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant 2008; 23: 904-909.
3. Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE: The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int 2011; 79: 1361-1369.
4. Gomez H, Ince C, De Backer D, Pickkers P, Payen D, Hotchkiss J, Kellum JA: A unified theory of sepsis-induced acute kidney injury: Inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock 2014; 41: 3-11.
5. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J: Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356: 2139-2143.
6. Janssen van Doorn K, Spapen H, Geers C, Diltoer M, Shabana W: Sepsis-related acute kidney injury: a protective effect of drotrecogin alpha (activated) treatment? Acta Anaesthesiol Scand 2008; 52: 1259-1264.
7. Heemskerk S, Masereeuw R, Moesker O, Bouw MP, van der Hoeven JG, Peters WH, Russel FG, Pickkers P, Group AS: Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med 2009; 37: 417-423, e411.
8. Pickkers P, Heemskerk S, Schouten J, Laterre PF, Vincent JL, Beishuizen A, Jorens PG, Spapen H, Bulitta M, Peters WH, van der Hoeven JG: Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebocontrolled trial. Crit Care 2012; 16:R14.
9. Millan JL: Alkaline phosphatases: structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes. Purinergic Signal 2006; 2: 335-341.
10. Cohen J: The immunopathogenesis of sepsis. Nature 2002; 420: 885-891.
11. Bentala H, Verweij WR, Huizinga-Van der Vlag A, van Loenen-Weemaes AM, Meijer DK, Poelstra K: Removal of phosphate from lipid a as a strategy to detoxify lipopolysaccharide. Shock 2002; 18: 561-566.
12. Pickkers P, Snellen F, Rogiers P, Bakker J, Jorens P, Meulenbelt J, Spapen H, Tulleken JE, Lins R, Ramael S, Bulitta M, van der Hoeven JG: Clinical pharmacology of exogenously administered alkaline phosphatase. Eur J Clin Pharmacol 2009; 65: 393-402.
13. Beumer C, Wulferink M, Raaben W, Fiechter D, Brands R, Seinen W: Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets. J Pharmacol Exp Ther 2003; 307: 737-744.
14. Verweij WR, Bentala H, Huizinga-van der Vlag A, Miek van Loenen-Weemaes A, Kooi K, Meijer DK, Poelstra K: Protection against an Escherichia coli-induced sepsis by alkaline phosphatase in mice. Shock 2004; 22: 174-179.
15. van Veen SQ, van Vliet AK, Wulferink M, Brands R, Boermeester MA, van Gulik TM: Bovine intestinal alkaline phosphatase attenuates the inflammatory response in secondary peritonitis in mice. Infect Immun 2005; 73: 4309-4314.
16. Koyama I, Matsunaga T, Harada T, Hokari S, Komoda T: Alkaline phosphatases reduce toxicity of lipopolysaccharides in vivo and in vitro through dephosphorylation. Clin Biochem 2002; 35: 455-461.
17. Campbell EL, MacManus CF, Kominsky DJ, Keely S, Glover LE, Bowers BE, Scully M, Bruyninckx WJ, Colgan SP: Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. Proc Natl Acad Sci USA 2010; 107: 14298-14303.
18. Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC: Adenosine 5 '-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 2006; 112: 358-404.
19. Bauerle JD, Grenz A, Kim JH, Lee HT, Eltzschig HK: Adenosine generation and signaling during acute kidney injury. J Am Soc Nephrol 2011; 22: 14-20.
20. Parmely MJ, Zhou WW, Edwards CK 3rd, Borcherding DR, Silverstein R, Morrison DC: Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol 1993; 151: 389-396.
21. Sullivan GW, Fang G, Linden J, Scheld WM: A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J Infect Dis 2004; 189: 1897-1904.
22. Gallos G, Ruyle TD, Emala CW, Lee HT: A1 adenosine receptor knockout mice exhibit increased mortality, renal dysfunction, and hepatic injury in murine septic peritonitis. Am J Physiol Renal Physiol 2005; 289:F369-F376.
23. Lee HT, Kim M, Joo JD, Gallos G, Chen JF, Emala CW: A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. Am J Physiol Regul Integr Comp Physiol 2006; 291:R959-R969.
24. Kiffer-Moreira T, Sheen CR, Gasque KC, Bolean M, Ciancaglini P, van Elsas A, Hoylaerts MF, Millan JL: Catalytic signature of a heatstable, chimeric human alkaline phosphatase with therapeutic potential. PLoS One 2014; 9:e89374.
25. Peters E, Heemskerk S, Masereeuw R, Pickkers P: Alkaline phosphatase: a possible treatment for sepsis-associated acute kidney injury in critically ill patients. Am J Kidney Dis 2014, DOI: 10.1053/j.ajkd.2013.11.027.
26. AM-Pharma presents positive data from recap preclinical study at ASN meeting. 2013. http://www.am-pharmacom/blog/2013/11/ am-pharma-presents-positive-data-fromrecap-preclinical-study-at-asn-meeting (accessed March 26, 2014).
27. AM-Pharma announces positive phase I data on recap for acute kidney injury. 2014. http:// www.am-pharmacom/blog/2014/03/ampharma-announces-positive-phase-i-dataon-recap-for-acute-kidney-injury (accessed March 27, 2014).